Who Paid My Doc
An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Research payments
$4,592,114
Through program year 2024, $4,592,114 in research payments was reported against An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder, across 636 payments, paid by ITI, Inc..
- Paid by
- ITI, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $690,805 | 130 |
| 2023 | Research | $2,370,952 | 294 |
| 2022 | Research | $1,530,357 | 212 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Shivkumar Hatti Media, PA Named on 41 payments
- Arifulla Khan Bellevue, WA Named on 39 payments
- Nader Oskooilar Newport Beach, CA Named on 35 payments
- Nick Vatakis New York, NY Named on 31 payments
- Rishi Kakar Tamarac, FL Named on 30 payments
- Ronald Brenner Rockville Centre, NY Named on 27 payments
- Irina Mezhebovsky Brookline, MA Named on 25 payments
- Sameer Hassamal La Verne, CA Named on 25 payments
- Paul Gross Allentown, PA Named on 25 payments
- Ashok Patel Toms River, NJ Named on 24 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.